Four doses of mRNA vaccine benefit people living with HIV receiving anti-retroviral therapy
A CITF-funded study published in AIDS, demonstrated that fourth COVID-19 vaccine doses, irrespective of whether they are monovalent or bivalent, benefit people living with HIV (PLWH) who receive anti-retroviral therapies (ART), including those who have already experienced a SARS-CoV-2 infection.